- Oops!Something went wrong.Please try again later.
Cassava Sciences is now conducting phase 3 trials for its lead drug candidate, an Alzheimer's treatment called simufilam. Skeptics of the company's research want the FDA to halt those trials to investigate claims of data manipulation. President and CEO Remi Barbier sounded defiant in a recent announcement: "We stand committed to translate what we believe is a promising scientific breakthrough into a potentially meaningful treatment for people with Alzheimer’s disease. The rest is noise.”